e-tender for procurement of drug items under table-a, for two years from the date of aoc. , amphotericin b 50 mg inj. , betahistine tab ip 8 mg , bortezomib 2mg inj. (powder for reconstitution)/vial , budesonide 0.5 mg/2ml respules , clotrimazole vaginal tab ip 500 mg , cyclosporine cap. 50 mg , dicyclomine hydrochloride inj 10 mg/ ml in 2 ml vial/amps. , docetaxel inj 120 mg , doxorubicin inj. 10mg. , doxorubicin inj. 50mg. , epirubicin 10mg inj. , epirubicin inj. 50 mg. , gemcitabine inj. 1gm. vial , pemetrexed 100 mg inj. , promethazine hcl inj. i.p. 25 mg/ml - 2ml ampoule , rabeprazole 20 mg tablets , ranitidine inj. i.p. 25mg/ml. - 2ml/ ampoule , telmisartan tab 40 mg , temozolamide cap. i.p. 250 mg. , important note: 1. all prospective bidders are requested to quote the rate in boq as per accounting unit & item specification as mentioned in the table-a. wrong quoting of the rate in boq will be dealt with as per penal provisions of the t&c of the tender. 2. quality of the product supplied, may be ascertained by testing / physical examination by the experts at any stage of the tender period. 3. the prospective bidders of the said tender are requested to make a declaration in affidavit under annexure vi(b)in case of sole manufacturer/importer (i.e. proprietary in nature). 4. if the item(s) under sole manufacturer / importer is (are) proprietary in nature, quarterly intimation is solicited from the approved bidders positively regarding the status of their item(s) proprietary in nature, otherwise their item(s) will be blocked in the smis. 5. in case of tie bid, decision will be taken by the tia as per g.o. no. 2320-f(y), dated 07.06.2022 issued from finance department audit branch (group t).